Li Ruo-Lan, Dong Tai-Wei, Wei Ji-Gang, Gao Feng, Li Min, Bai Yang, Wei Pei-Feng, Xi Miao-Miao
College of Pharmacy, Shaanxi University of Chinese Medicine, Shiji Road, Qindu District, Xianyang, Shaanxi 712046, China.
Tongchuan Mineral Bureau Central Hospital, No. 15, Chuankou Road, Wangyi District, Tongchuan, Shaanxi 727000, China.
Evid Based Complement Alternat Med. 2020 Sep 29;2020:5754823. doi: 10.1155/2020/5754823. eCollection 2020.
To systematically evaluate the effectiveness of Shenqi Jiangtang granule (SQJT) in the treatment of type 2 diabetes.
We searched CNKI, Wanfang Data, VIP, and PubMed databases to collect randomized controlled trials (RCT) of Shenqi Jiangtang granules in the treatment of type 2 diabetes. The search time was from January 2014 to the present. Data were extracted, and quality was evaluated. Metadata analysis of the extracted data was carried out using RevMa5.2 software. The final results are expressed in relative risk (RR), mean difference (MD), and 95% CI.
This study included a total of 13 studies, 1160 subjects. Meta-analysis results showed that the test group was better than the control group (RR = 1.26, 95% CI 1.18-1.34, < 0.00001). The fasting blood glucose, postprandial blood glucose, and glycated hemoglobin of the test group were also significantly better than those of the control group.
Shenqi Jiangtang granules have a certain clinical effect and low adverse reaction rate for the treatment or adjuvant treatment of type 2 diabetes. At present, the drug has been widely used in clinical practice, but a large number of large-sample clinical trials are needed to further verify its specific efficacy and safety.
系统评价参芪降糖颗粒治疗2型糖尿病的有效性。
检索中国知网、万方数据、维普资讯和PubMed数据库,收集参芪降糖颗粒治疗2型糖尿病的随机对照试验(RCT)。检索时间为2014年1月至目前。提取数据并进行质量评价。使用RevMa5.2软件对提取的数据进行Meta分析。最终结果以相对危险度(RR)、均差(MD)和95%可信区间(CI)表示。
本研究共纳入13项研究,1160例受试者。Meta分析结果显示,试验组优于对照组(RR = 1.26,95%CI 1.18 - 1.34,P < 0.00001)。试验组的空腹血糖、餐后血糖和糖化血红蛋白也显著优于对照组。
参芪降糖颗粒治疗或辅助治疗2型糖尿病具有一定临床疗效且不良反应发生率低。目前该药物已在临床广泛应用,但仍需大量大样本临床试验进一步验证其确切疗效和安全性。